{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih4cozsplxrxyyicldyjslrrbuxmpajbmabkhnoc3jlcyh5h2nduu",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mf4lnz4qk4x2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigo6jhodxsmwz2dotd7ac7bv3k2vaq7xj4flbzsw4afk2ngtghwdq"
    },
    "mimeType": "image/jpeg",
    "size": 38022
  },
  "path": "/2026/02/17/compass-pathways-comp360-psilocybin-severe-depression-trial-results/?utm_campaign=rss",
  "publishedAt": "2026-02-17T11:30:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Breaking News",
    "Health",
    "Pharma",
    "biotechnology",
    "drug development",
    "Mental Health",
    "Pharmaceuticals",
    "Policy",
    "psychedelics",
    "STAT+"
  ],
  "textContent": "COMP360 could be the first psilocybin-based medicine to win approval.",
  "title": "STAT+: Compass says its psilocybin drug helped patients with severe depression in two trials",
  "updatedAt": "2026-02-17T22:32:32.000Z"
}